[1] Marklevitz J, Harris LK. Improved annotations of 23 differentially expressed hypothetical proteins in methicillin resistant S. aureus[J] . Bioinformation, 2017, 13(4):104-110. [2] Tickler IA, Goering RV, Mediavilla JR, et al. Continued expansion of USA300-like methicillin-resistant Staphylococcus aureus(MRSA)among hospitalized patients in the United States[J] . Diagn Microbiol Infect Dis, 2017(in press). [3] 李海清, 王凤玲, 刘静. 骨外系感染患者金黄色葡萄球菌耐药性分析[J] . 国际检验医学杂志, 2013, 34(13):1765-1767. [4] 马翔宇, 易龙, 宋治远. 医源性MRSA感染及其防治研究进展[J] . 临床医学, 2003, 23(5):53-54. [5] Ping L, Blair C, Amy S et al. El-Solh Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function:a retrospective, cohort analysis[J] . BMC Nephrology, 2017, 18:168-177. [6] Suresh P, Hiroshi H, Atmika P, et al. Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates[J] . Drug Discov Ther, 2017, 1:1-6. [7] 赵博, 陈取, 杜志成, 等. 万古霉素、替考拉宁、利奈唑胺、达托霉素对耐甲氧西林金黄色葡萄球菌抗菌活性及药物优弊的研究[J] . 中国实用医药, 2011, 6(18):242-243. [8] Darren C, Kenneth C L, Min JY, et al Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia[J] . Diagnostic Microbiology and Infectious Disease, 2015, 83(2):193-197. [9] Gerson SL, Kaplan SL, Bruss JB, et al. Hematologiceffects of linezolid:Summary of clinical experience[J] . Antimicrob Agents Chemother, 2002, 46(8):2723-2726. [10] Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections:A prospective case series[J] . Diagn Microbiol Infect Dis, 2007, 59(2):173-179. [11] Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but highrates of adverse reactions during linezolidtherapy for serious infection:A proposed protocol for monitoring therapy in complex[J] . Antimicrob Antimicrob Agents Chemother, 2006, 50(4):1599-1602. [12] 杨元勋, 李刚, 钱正刚. 利奈唑胺不良反应文献分析[J] . 实用药物与临床, 2013, 16(7):621-623. [13] Shahzad R, Khan AL, Bilal S, et al. Plant growth-promoting endophytic bacteria versus pathogenic infections:an example of Bacillus amyloliquefaciens RWL-1 and Fusarium oxysporum f. sp. lycopersici in tomato[J] . Peer J, 2017, 5:e3107. [14] Vinodkumar S, Nakkeeran S, et al. Biocontrol potentials of antimicrobial peptide producing bacillus species:multifaceted antagonists for the management of stem rot of carnation caused by Sclerotinia sclerotiorum[J] . Front Microbiol, 2017, 8:446. [15] Masmoudi F, Ben Khedher S, Kamoun A, et al. Combinatorial effect of mutagenesis and medium component optimization on Bacillus amyloliquefaciens antifungal activity and efficacy in eradicating Botrytis cinerea[J] . Microbiol Res, 2017, 197:29-38. [16] Gotor-Vila A, Teixidó N, Di Francesco A, et al. Antifungal effect of volatile organic compounds produced by Bacillus amyloliquefaciens CPA-8 against fruit pathogen decays of cherry[J] . Food Microbiol, 2017, 64:219-225. [17] 关晓欢, 姜华. 解淀粉芽孢杆菌研究进展[J] . 生物技术世界, 2013(1):4, 9. [18] Lee HA, Kim JH. Isolation of Bacillus amyloliquefaciens strains with antifungal activities from Meju[J] . Preventive Nutrition & Food Science, 2012, 17(1):64-70. [19] Ji SH, Paul NC, Deng JH, et al. Biocontrol activity of Bacillus amyloliquefaciens CNU114001 against fungal plant diseases[J] . Mycobiology, 2013, 41(4):234-242. [20] 杨艳红, 李世川, 兰世玉, 等. 一株产耐酸性α—淀粉酶菌株的鉴定及其酶学性质研究[J] , 天然产物研究与开发, 2015, (9):1544-1549. [21] 董文波. 细菌药敏最低抑菌浓度微孔检测板的研制[J] . 中南医学科学杂志, 2000(2):47-48, 50. [22] 出晓铭, 林毅雄, 张珅, 等. 生防菌解淀粉芽孢杆菌抗菌蛋白的研究进展[J] . 包装与食品机械, 2014, 32(6):49-54. [23] Pretorius D, Van RJ, et al. Enhanced production of antifungal lipo-peptides by Bacillus amyloliquefaciens for biocontrol of postharvest disease[J] . New Biotechnology, 2015, 32(2):243-252. [24] Kadaikunnan S, Rejiniemon TS, Khaled JM, et al. In-vitro antibacterial, antifungal, antioxidant and functional properties of Bacillus amyloliquefaciens[J] . Annals of Clinical Microbiology and Antimicrobials, 2015, 14(9):1-11. [25] 张娟, 杨彩梅, 曹广添, 等. 解淀粉芽孢杆菌及其作为益生菌的应用[J] . 动物营养学报, 2014, 26(4):863-867. [26] Arias AA, Ongena M, Devreese B, et al. Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1[J] . PLoS One, 2013, 8(12):1-10. [27] 杨桥, 瀚文菊, 张文俊, 等. 一株新型大环内酯抗生素海洋解淀粉芽孢杆菌的分离鉴定[J] . 中华航海医学与高气压医学杂志, 2009, 16(2):92-95. [28] Ravut RR, Jacobt MR, Chent XL, et al. Bacillusin A, antibacterial macrodiolide from Bacillus amyloliquefaciens AP 183[J] . Journal of Natural Products, 2015, 78(4):924-928. [29] Jeyanthi V, Velusamy P. Anti-methicillin resistant Staphylococcus aureus compound isolation from halophilic Bacillus amyloliquefaciens MHB1 and Determination of its mode of action using electron microscope and flow cytometry analysis[J] . Indian Journal of Microbiology, 2016, 56(2):148-157. [30] Arguelles-Arias A, Ongena M, Halimi B, et al. Bacillus amyloliquefaciens GA1 as a source of potent antibiotics and other secondary metabolites for biocontrol of plant pathogens[J] . Microbial Cell Factories, 2009, 8:63. [31] 谢练武, 李翔, 欧阳永长, 等. 抗生素作用新靶点的发掘策略[J] . 中国抗生素杂志, 2007, 32(11):641-646. |